Thousand Oaks-based Amgen beat analysts’ expectations when it reported its earnings for the second quarter on Aug. 3, but more importantly, the company reaffirmed its position that it can close the pending acquisition of Horizon Therapeutics before the end of the year. The biotech giant reported net income grew 4.5% year over year from $1.32…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
